SPACs are resurging as a virtually hassle-free alternative to IPOs, but are just now becoming a factor for biotech, reports BioSpace. Biotech is a burgeoning business, and non-traditional investors with little biotech knowledge or expertise gravitate to biotech SPACS. They have money to invest and want to get in on the ground floor of what they hope will become the next Amgen or Genentech. Read more.
Report: Biotech Becoming Attracted to SPACs
